SlideShare a Scribd company logo
1 of 25
Case study



        Mahmoud said
 A 30 years old lady referred to the renal clinic complaining of
   L.L is free except for soft pitting oedema, morning puffiness , and
   prot.2+ in urine .
 Chest ,heart ,abdomen and LND examination all are free
 she is non-diabetic but hypertensive since 5 years
 No history of NSAID
 On examination :
    B.P:150/100
    Pulse:90
    L.L edema :2+
Which investigations would you ask for

         in this case ?????
 24hr urinary protein:4g/day
 Urea: 18
 Creat:0.6
 cholest: 350mg/dl
 T.G: 200mg/dl
 S.albumin :2.7
 ESR: 80/120   ????
 ANA ,AntiDsDNA,C3 all are of normal range
 HCVAb , HBSAg negative.
 PT: 100%              INR: 1
ESR in nephrotic syndrome
The erythrocyte sedimentation rate (ESR) is
 elevated (greater than 25 mm/h by the
 Westergren method) in almost all patients with
 the nephrotic syndrome.(T/F)



This finding alone is not an indication to evaluate a
 patient for an underlying systemic disorder (T/F)
ESR in nephrotic syndrome


A direct relation between the degree of proteinuria
 and the ESR has been noted in patients with
 glomerular disease in which the ESR was
 approximately 10 times the daily rate of protein
 excretion
To biopsy or not ?




Biopsy was done
Microscopic picture:
with H&E,PAS,trichrome,and congo-red revealed


Widening of the mesangial area-↑glomerular cellularity

                                   +
Thickening of GBM, podocytes were hypertrophied.

Renal tubules-intersetium and the included arterioles were unremarkable
 Immunohistochemical for IgG,IgM,IgA


IgG: moderate (++) positive staining in
  subendothelial area
IgA: mild (+) positive staining in subendothelial area
IgM:(+/-) positive staining
 What is your histopathological diagnosis??
A) membranous GN
B) Mesangioproliferative GN
C) Membranoproliferative Type I
d) Membranoproliferative typeIII
e) non of the above
A) Membranous GN
B) Mesangioproliferative GN
C) Membranoproliferative Type I
d) Membranoproliferative typeIII
e) non of the above
Well
done
Microscopic picture:
with H&E,PAS,trichrome,and congo-red revealed

Widening of the mesangial area-
↑glomerular cellularity

               +
Thickening of GBM, podocytes were
hypertrophied.


Renal tubules-intersetium and the included arterioles were
unremarkable
 So Why is type I not III?


   Immunohistochemical for IgG,IgM,IgA


IgG: moderate (++) positive staining in
  subendothelial area
IgA: mild (+) positive staining in subendothelial
  area
IgM:(+/-) positive staining
EM in Renal Biopsy (KDIGO
guidelines)
 sufficient tissue is needed to perform not only an
examination by light microscopy, but also
immunohistochemical staining to detect immune
reactants (including immunoglobulins and
complement components),and
   electron microscopy to define precisely the location,
extent and, potentially, the specific characteristics of the
immune deposits. We recognize that electron
microscopy is
not routinely available in many parts of the world, but
the
additional information defined by this technique may
modify
and even change the histologic diagnosis, and may
influence
therapeutic decisions; hence, it is recommended
 So you now Know this is a case of
                   MPGN type I

What will you do ? Based on Evidence !!!!!!
 She was put on
  ARBs & ACEI
 Omega 3 plus ????
 Cyclosporin 50 mg 1*2 ???????????
 Steroids 40 mg/day with tapering the dose
24 hr.urinary                s.creatinine
   Date     protein g/day s.albumin g/dl    mg/dl       C0
 1.4.2011          4            2.7           0.6
1.6.2011           5                           1        88
 1.7.2011          6             3            0.7       142
1.8.2011          14                          0.6
1.9.2011           3                          0.7
1.10.2011        5.2            3.5
1.11.2011        1.3             4                      139
1.12.2011        1.2
1.1.2012         0.77
01-02-12         1.5            4.4           1.4       238
1.3.2012         1.8                          1.3
28.3.2012          4
 1.4.2011        2.6                          1.2
25.4.2011        0.8            4.5           1.1
1.6.2011         1.8                           1
 1.7.2011        1.3
1.8.2011           4                          0.9
1.9.2011         1.3
1.10.2011         2.7           3.9
During the period of treatment the patient suffered
  from severe headache that was not responsive
  to any line of treatment she was refereed to a
  neurologist . .
A CT scan was done but was unremarkable
MRI was also unremarkable
Bilateral papilledeoma was noted on FUNDUS
  examination and was diagnosed as pseudo tumor
  cerebri
Acetazolamide and thiazide diuretics was added
  along with increasing the dose of the steroids.
She had maevellous response and know she is
Prognosis in Idiopathic MPGN
Idiopathic MPGN in adults also carries
an unfavorable prognosis. Five years after biopsy,
  50% of patients either die or need renal
  replacement therapy (dialysis or transplantation).
  This proportion increases to 64% after 10 years.

         Risk of progression increases with
   elevated creatinine, nephrotic proteinuria, and
     severe hypertension or if a biopsy specimen
     shows more than 50% crescents or marked
                  interstitial fibrosis
So ,

after this what do you think the prognosis of this
 patient is?
Do you consider shifting cyclosporin to other
lines of



        immunosuppressive drugs is useful or not
?



                      and Why?
Thank you

More Related Content

What's hot

Dng hbv -kidney disease
Dng  hbv -kidney  diseaseDng  hbv -kidney  disease
Dng hbv -kidney disease
FarragBahbah
 
Membranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMembranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis s
Mohammad Manzoor
 
Membranous nephropathy
Membranous nephropathyMembranous nephropathy
Membranous nephropathy
Vishal Golay
 

What's hot (20)

Hepatitis c virus associated with renal disease
Hepatitis c virus associated with renal diseaseHepatitis c virus associated with renal disease
Hepatitis c virus associated with renal disease
 
clinical approach to Rapidly Progressive Glomerulonephritis
clinical approach to Rapidly Progressive Glomerulonephritisclinical approach to Rapidly Progressive Glomerulonephritis
clinical approach to Rapidly Progressive Glomerulonephritis
 
Haemodialysis related ascites prof. mohamed sobh
Haemodialysis related ascites prof. mohamed sobhHaemodialysis related ascites prof. mohamed sobh
Haemodialysis related ascites prof. mohamed sobh
 
Acute Liver Failure Update
Acute Liver Failure UpdateAcute Liver Failure Update
Acute Liver Failure Update
 
Jaundice
JaundiceJaundice
Jaundice
 
IgA nephropathy
IgA nephropathyIgA nephropathy
IgA nephropathy
 
Acid base balance
Acid base balanceAcid base balance
Acid base balance
 
Anaemia of chronic kidney disease GUIDELINES TO PRACTICE 2013
Anaemia of chronic kidney disease GUIDELINES TO PRACTICE  2013Anaemia of chronic kidney disease GUIDELINES TO PRACTICE  2013
Anaemia of chronic kidney disease GUIDELINES TO PRACTICE 2013
 
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. GawadMajor Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
 
Dng hbv -kidney disease
Dng  hbv -kidney  diseaseDng  hbv -kidney  disease
Dng hbv -kidney disease
 
Management of lupus nephritis
Management of lupus nephritisManagement of lupus nephritis
Management of lupus nephritis
 
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadHemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
 
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. GawadIs It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
 
Aki updated
Aki updatedAki updated
Aki updated
 
Membranous Nephropathy - Management Algorithm - Dr. Gawad
Membranous Nephropathy - Management Algorithm - Dr. GawadMembranous Nephropathy - Management Algorithm - Dr. Gawad
Membranous Nephropathy - Management Algorithm - Dr. Gawad
 
Hepatic encephalopathy for student by dr Mohammed Hussien
Hepatic encephalopathy for student by dr Mohammed Hussien Hepatic encephalopathy for student by dr Mohammed Hussien
Hepatic encephalopathy for student by dr Mohammed Hussien
 
Membranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMembranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis s
 
Cardiorenal Syndrome
Cardiorenal SyndromeCardiorenal Syndrome
Cardiorenal Syndrome
 
Membranous nephropathy
Membranous nephropathyMembranous nephropathy
Membranous nephropathy
 

Viewers also liked

Case Study Presentation-Rachael Joseph
Case Study Presentation-Rachael JosephCase Study Presentation-Rachael Joseph
Case Study Presentation-Rachael Joseph
Rachael Joseph
 
Renal pathology
Renal pathologyRenal pathology
Renal pathology
raj kumar
 

Viewers also liked (20)

MPGN Pam
MPGN  PamMPGN  Pam
MPGN Pam
 
Membranoproliferative Glomerulonephritis - Diagnostic Road for Etiology - Dr....
Membranoproliferative Glomerulonephritis - Diagnostic Road for Etiology - Dr....Membranoproliferative Glomerulonephritis - Diagnostic Road for Etiology - Dr....
Membranoproliferative Glomerulonephritis - Diagnostic Road for Etiology - Dr....
 
Treatment of MPGN , What is the evidence?
Treatment of  MPGN , What is the evidence?Treatment of  MPGN , What is the evidence?
Treatment of MPGN , What is the evidence?
 
MPGN
MPGNMPGN
MPGN
 
MPGN/MCGN
MPGN/MCGNMPGN/MCGN
MPGN/MCGN
 
Pathophysiology of Membranous GN
Pathophysiology of Membranous GNPathophysiology of Membranous GN
Pathophysiology of Membranous GN
 
An Unusual Case Of Renal Failure
An Unusual Case Of Renal FailureAn Unusual Case Of Renal Failure
An Unusual Case Of Renal Failure
 
Membranoproliferative glomerulonephritis, nephritic nephrotic syndrome
Membranoproliferative glomerulonephritis, nephritic nephrotic syndromeMembranoproliferative glomerulonephritis, nephritic nephrotic syndrome
Membranoproliferative glomerulonephritis, nephritic nephrotic syndrome
 
Case Study Presentation-Rachael Joseph
Case Study Presentation-Rachael JosephCase Study Presentation-Rachael Joseph
Case Study Presentation-Rachael Joseph
 
renal biopsy
renal biopsyrenal biopsy
renal biopsy
 
Mesangial proliferative GN
Mesangial proliferative GNMesangial proliferative GN
Mesangial proliferative GN
 
Special stains
Special stainsSpecial stains
Special stains
 
Approach to Rapidly Progressive Glomerulonephritis RPGN
Approach to Rapidly Progressive Glomerulonephritis RPGNApproach to Rapidly Progressive Glomerulonephritis RPGN
Approach to Rapidly Progressive Glomerulonephritis RPGN
 
Pathology Of Kidney
Pathology Of KidneyPathology Of Kidney
Pathology Of Kidney
 
Introduction to Renal Pathology
Introduction to Renal PathologyIntroduction to Renal Pathology
Introduction to Renal Pathology
 
Renal Histology
Renal HistologyRenal Histology
Renal Histology
 
Renal pathology
Renal pathologyRenal pathology
Renal pathology
 
Renal Pathology Tutorial
Renal Pathology TutorialRenal Pathology Tutorial
Renal Pathology Tutorial
 
Renal pathology
Renal pathologyRenal pathology
Renal pathology
 
Kidney histology
Kidney histologyKidney histology
Kidney histology
 

Similar to MPGN case presentation

4-3. Risk factors for IgAN. Rosanna Coppo (eng)
4-3. Risk factors for IgAN. Rosanna Coppo (eng)4-3. Risk factors for IgAN. Rosanna Coppo (eng)
4-3. Risk factors for IgAN. Rosanna Coppo (eng)
KidneyOrgRu
 
Sabari krishnan final clinical meet 2 copy
Sabari krishnan final clinical meet 2 copySabari krishnan final clinical meet 2 copy
Sabari krishnan final clinical meet 2 copy
pgimer chandigarh
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome
fatmakhafage
 
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
Paul Pérez
 

Similar to MPGN case presentation (20)

OSCE Pediatrics Dr.Mehta Hospital 2012
OSCE Pediatrics Dr.Mehta Hospital 2012OSCE Pediatrics Dr.Mehta Hospital 2012
OSCE Pediatrics Dr.Mehta Hospital 2012
 
Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases o...
Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases o...Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases o...
Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases o...
 
Vars
VarsVars
Vars
 
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
 
4-3. Risk factors for IgAN. Rosanna Coppo (eng)
4-3. Risk factors for IgAN. Rosanna Coppo (eng)4-3. Risk factors for IgAN. Rosanna Coppo (eng)
4-3. Risk factors for IgAN. Rosanna Coppo (eng)
 
Outcomes of high grade thalamic gliomas in a cancer centre
Outcomes of high grade thalamic gliomas in a cancer centreOutcomes of high grade thalamic gliomas in a cancer centre
Outcomes of high grade thalamic gliomas in a cancer centre
 
Osce cuckoos
Osce cuckoosOsce cuckoos
Osce cuckoos
 
Nephrotic Syndrome 2023.pptx
Nephrotic Syndrome 2023.pptxNephrotic Syndrome 2023.pptx
Nephrotic Syndrome 2023.pptx
 
Peter Scanlon: diabetic eye screening, past present and future part 2
Peter Scanlon: diabetic eye screening, past present and future part 2Peter Scanlon: diabetic eye screening, past present and future part 2
Peter Scanlon: diabetic eye screening, past present and future part 2
 
Resistin
ResistinResistin
Resistin
 
Sabari krishnan final clinical meet 2 copy
Sabari krishnan final clinical meet 2 copySabari krishnan final clinical meet 2 copy
Sabari krishnan final clinical meet 2 copy
 
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Copy of osce cme24.04.2012 calicut
Copy of osce cme24.04.2012 calicut Copy of osce cme24.04.2012 calicut
Copy of osce cme24.04.2012 calicut
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome
 
The Role of Extracorporeal Photopheresis in Scleroderma
The Role of Extracorporeal Photopheresis in SclerodermaThe Role of Extracorporeal Photopheresis in Scleroderma
The Role of Extracorporeal Photopheresis in Scleroderma
 
Ig A nephropathy (Cresentric) by Dr. Shami (SKIMS)
Ig A nephropathy (Cresentric) by Dr. Shami (SKIMS)Ig A nephropathy (Cresentric) by Dr. Shami (SKIMS)
Ig A nephropathy (Cresentric) by Dr. Shami (SKIMS)
 
Salon b 13 kasim 15.45 17.00 müge aydoğdu-ing
Salon b 13 kasim 15.45 17.00 müge aydoğdu-ingSalon b 13 kasim 15.45 17.00 müge aydoğdu-ing
Salon b 13 kasim 15.45 17.00 müge aydoğdu-ing
 
Assessment of the effects of highly active antiretroviral therapy
Assessment of the effects of highly active antiretroviral therapyAssessment of the effects of highly active antiretroviral therapy
Assessment of the effects of highly active antiretroviral therapy
 
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
 

More from Mohamed E. Elrggal (7)

Cystic kidney diseases m. mustafa
Cystic kidney diseases m. mustafaCystic kidney diseases m. mustafa
Cystic kidney diseases m. mustafa
 
How to optimize the management of CKD patient ?
How to optimize the management of CKD patient ?How to optimize the management of CKD patient ?
How to optimize the management of CKD patient ?
 
Clinical pharmacology in diuretic use kuc club august 2019
Clinical pharmacology in diuretic use kuc club august 2019Clinical pharmacology in diuretic use kuc club august 2019
Clinical pharmacology in diuretic use kuc club august 2019
 
Updates about Metformin use in CKD
Updates about Metformin use in CKDUpdates about Metformin use in CKD
Updates about Metformin use in CKD
 
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome
 
Renal disease and pregnancy
Renal disease and pregnancyRenal disease and pregnancy
Renal disease and pregnancy
 
Cystic kidney diseases dr.a.hassan end123
Cystic kidney diseases dr.a.hassan end123Cystic kidney diseases dr.a.hassan end123
Cystic kidney diseases dr.a.hassan end123
 

Recently uploaded

BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
SoniaTolstoy
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Krashi Coaching
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 

Recently uploaded (20)

BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Disha NEET Physics Guide for classes 11 and 12.pdf
Disha NEET Physics Guide for classes 11 and 12.pdfDisha NEET Physics Guide for classes 11 and 12.pdf
Disha NEET Physics Guide for classes 11 and 12.pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
 

MPGN case presentation

  • 1. Case study Mahmoud said
  • 2.  A 30 years old lady referred to the renal clinic complaining of L.L is free except for soft pitting oedema, morning puffiness , and prot.2+ in urine . Chest ,heart ,abdomen and LND examination all are free she is non-diabetic but hypertensive since 5 years No history of NSAID  On examination : B.P:150/100 Pulse:90 L.L edema :2+
  • 3. Which investigations would you ask for in this case ?????
  • 4.  24hr urinary protein:4g/day  Urea: 18  Creat:0.6  cholest: 350mg/dl  T.G: 200mg/dl  S.albumin :2.7  ESR: 80/120 ????  ANA ,AntiDsDNA,C3 all are of normal range  HCVAb , HBSAg negative.  PT: 100% INR: 1
  • 5. ESR in nephrotic syndrome The erythrocyte sedimentation rate (ESR) is elevated (greater than 25 mm/h by the Westergren method) in almost all patients with the nephrotic syndrome.(T/F) This finding alone is not an indication to evaluate a patient for an underlying systemic disorder (T/F)
  • 6. ESR in nephrotic syndrome A direct relation between the degree of proteinuria and the ESR has been noted in patients with glomerular disease in which the ESR was approximately 10 times the daily rate of protein excretion
  • 7. To biopsy or not ? Biopsy was done
  • 8. Microscopic picture: with H&E,PAS,trichrome,and congo-red revealed Widening of the mesangial area-↑glomerular cellularity + Thickening of GBM, podocytes were hypertrophied. Renal tubules-intersetium and the included arterioles were unremarkable
  • 9.  Immunohistochemical for IgG,IgM,IgA IgG: moderate (++) positive staining in subendothelial area IgA: mild (+) positive staining in subendothelial area IgM:(+/-) positive staining
  • 10.  What is your histopathological diagnosis?? A) membranous GN B) Mesangioproliferative GN C) Membranoproliferative Type I d) Membranoproliferative typeIII e) non of the above
  • 11. A) Membranous GN B) Mesangioproliferative GN C) Membranoproliferative Type I d) Membranoproliferative typeIII e) non of the above
  • 13. Microscopic picture: with H&E,PAS,trichrome,and congo-red revealed Widening of the mesangial area- ↑glomerular cellularity + Thickening of GBM, podocytes were hypertrophied. Renal tubules-intersetium and the included arterioles were unremarkable
  • 14.  So Why is type I not III? Immunohistochemical for IgG,IgM,IgA IgG: moderate (++) positive staining in subendothelial area IgA: mild (+) positive staining in subendothelial area IgM:(+/-) positive staining
  • 15.
  • 16. EM in Renal Biopsy (KDIGO guidelines) sufficient tissue is needed to perform not only an examination by light microscopy, but also immunohistochemical staining to detect immune reactants (including immunoglobulins and complement components),and electron microscopy to define precisely the location, extent and, potentially, the specific characteristics of the immune deposits. We recognize that electron microscopy is not routinely available in many parts of the world, but the additional information defined by this technique may modify and even change the histologic diagnosis, and may influence therapeutic decisions; hence, it is recommended
  • 17.  So you now Know this is a case of MPGN type I What will you do ? Based on Evidence !!!!!!
  • 18.  She was put on ARBs & ACEI Omega 3 plus ???? Cyclosporin 50 mg 1*2 ??????????? Steroids 40 mg/day with tapering the dose
  • 19. 24 hr.urinary s.creatinine Date protein g/day s.albumin g/dl mg/dl C0 1.4.2011 4 2.7 0.6 1.6.2011 5 1 88 1.7.2011 6 3 0.7 142 1.8.2011 14 0.6 1.9.2011 3 0.7 1.10.2011 5.2 3.5 1.11.2011 1.3 4 139 1.12.2011 1.2 1.1.2012 0.77 01-02-12 1.5 4.4 1.4 238 1.3.2012 1.8 1.3 28.3.2012 4 1.4.2011 2.6 1.2 25.4.2011 0.8 4.5 1.1 1.6.2011 1.8 1 1.7.2011 1.3 1.8.2011 4 0.9 1.9.2011 1.3 1.10.2011 2.7 3.9
  • 20.
  • 21. During the period of treatment the patient suffered from severe headache that was not responsive to any line of treatment she was refereed to a neurologist . . A CT scan was done but was unremarkable MRI was also unremarkable Bilateral papilledeoma was noted on FUNDUS examination and was diagnosed as pseudo tumor cerebri Acetazolamide and thiazide diuretics was added along with increasing the dose of the steroids. She had maevellous response and know she is
  • 22. Prognosis in Idiopathic MPGN Idiopathic MPGN in adults also carries an unfavorable prognosis. Five years after biopsy, 50% of patients either die or need renal replacement therapy (dialysis or transplantation). This proportion increases to 64% after 10 years. Risk of progression increases with elevated creatinine, nephrotic proteinuria, and severe hypertension or if a biopsy specimen shows more than 50% crescents or marked interstitial fibrosis
  • 23. So , after this what do you think the prognosis of this patient is?
  • 24. Do you consider shifting cyclosporin to other lines of immunosuppressive drugs is useful or not ? and Why?